by Anna Smith Cambridge University Hospital NHS Foundation Trust has announced that its inflammatory bowel disease (IBD) research has hit its recruitment target of 25,000 …
Men with breast cancer have significantly fewer treatment options than women with the disease, partly due to exclusion from many clinical trials. A new document …
AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the …
Eli Lilly on Monday won an expanded approval for its psoriasis and arthritis drug Taltz, securing a Food and Drug Administration OK that should help …
AstraZeneca and GlaxoSmithKline have long locked horns in their battle for respiratory supremacy with the latter holding the clear advantage in triple-drug inhaler market. Can …
A 10-year wait obviously didn’t discourage Kyowa Kirin from changing the FDA’s mind for its add-on Parkinson’s disease therapy. Tuesday, the FDA finally approved the Japanese pharma’s …
AstraZeneca is still stinging after its SGLT2 diabetes drug Farxiga was waved off by the FDA in Type 1 disease. But here’s something that could …
Investors in The Medicines Company have Sept. 2 circled in red on their calendars. That’s the day the company plans to report the first pivotal …
Regeneron Pharmaceuticals said its experimental drug evinacumab significantly lowered “bad” cholesterol levels 49% compared to placebo in a Phase 3 study of patients with homozygous …
For the third time, the Food and Drug Administration cleared a cancer drug to treat tumors based on a specific genetic signature rather than by …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
